8-K: Forte Biosciences Secures $75 Million Through Public Offering to Extend Cash Runway into 2027

Forte Biosciences, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of common stock and pre-funded warrants, expecting to raise approximately $75 million in gross proceeds to fund its clinical and preclinical development into 2027.

Summary

• Forte Biosciences, Inc. priced a public offering of 5,630,450 shares of its common stock at $12.00 per share.
• The offering also includes 619,606 pre-funded warrants to purchase common stock at a price of $11.999 per pre-funded warrant, which represents the public offering price less a $0.001 exercise price.
• The company granted the underwriters a 30-day option to purchase up to an additional 937,508 shares of common stock at the public offering price.
• The gross proceeds from the offering are expected to be approximately $75.0 million before deducting underwriting discounts and commissions and other offering expenses, assuming no exercise of the option.
• Estimated net proceeds are approximately $70.0 million, or $80.5 million if the underwriters' option to purchase additional shares is exercised in full.
• The offering is expected to close on or about June 26, 2025, subject to satisfaction of customary closing conditions.
• Forte intends to use the net proceeds for working capital and other general corporate purposes, including funding clinical and preclinical development of its product candidate FB102 and other research activities.
• Based on the planned use of proceeds and existing cash, the company estimates that these funds will be sufficient to fund operating expenses and capital expenditure requirements into 2027.

Sentiment

Score: 8

Explanation: The successful pricing of a $75 million public offering significantly strengthens Forte Biosciences' financial position, providing an estimated cash runway into 2027. This capital infusion is crucial for advancing its clinical and preclinical development programs, particularly for its lead product candidate FB102, which is essential for a clinical-stage biopharmaceutical company.

Positives

• The public offering is expected to raise significant capital, with gross proceeds of approximately $75.0 million, providing substantial funding for company operations.
• The capital raise is projected to extend the company's cash runway, providing sufficient funds for operating expenses and capital expenditure requirements into 2027, enhancing financial stability.
• The funds will support the clinical and preclinical development of FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases, which is critical for a clinical-stage biopharmaceutical company.

Negatives

• The issuance of 5,630,450 shares of common stock and 619,606 pre-funded warrants will result in dilution for existing shareholders.

Risks

• Uncertainty regarding the Company's ability to successfully raise capital through the sale of securities or consummate the offering.
• The final terms of the offering may differ from current expectations.
• The satisfaction of customary closing conditions is not guaranteed, which could prevent the offering from closing.
• Prevailing market conditions could adversely affect the offering.
• General economic and market conditions, as well as geopolitical developments, pose risks to the company's business and financial results.
• Additional risks and uncertainties are detailed in the Company's Quarterly Report on Form 10-Q filed on May 15, 2025, and in its other filings with the SEC.

Future Outlook

Forte Biosciences expects the net proceeds from this offering, combined with its existing cash and cash equivalents, to be sufficient to fund its operating expenses and capital expenditure requirements into 2027. The funds are primarily allocated for working capital and general corporate purposes, including the advancement of its clinical and preclinical development programs for its product candidate, FB102.

Management Comments

• Forte cautions that statements included in this press release that are not a description of historical facts are forward-looking statements.
• These statements are based on Forte's current beliefs and expectations.
• Forward-looking statements include statements regarding the completion and timing of the offering and the anticipated use of proceeds from the offering.
• Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.
• Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Industry Context

This public offering by Forte Biosciences is a common strategy for clinical-stage biopharmaceutical companies to secure necessary capital for advancing their drug development pipelines. Given the high costs and lengthy timelines associated with clinical trials, particularly for autoimmune diseases, such capital raises are crucial for sustaining operations and progressing product candidates like FB102. The ability to raise $75 million indicates investor confidence in the company's therapeutic candidate and strategic direction, despite the inherent risks of drug development.

Stakeholder Impact

• Shareholders: Will experience dilution due to the issuance of new common stock and pre-funded warrants, but the capital raise provides financial stability and enables continued development, potentially increasing long-term value.
• Employees: Increased job security and continued funding for research and development activities.
• Customers (future): Continued development of FB102 could lead to new therapeutic options for autoimmune diseases.
• Creditors: Improved financial health and liquidity, reducing credit risk.

Next Steps

• Closing of the public offering, expected on or about June 26, 2025.
• Continued clinical and preclinical development of FB102.
• Filing of the final prospectus supplement and accompanying prospectus with the SEC.
• Company to make generally available to stockholders an earnings statement within sixteen (16) months after the effective date of the Registration Statement.
• Company to maintain a registrar and transfer agent for the Securities.
• Company to use its reasonable best efforts to list the Stock and Warrant Shares on the Exchange.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Public Offering, Common Stock, Pre-funded Warrants, Capital Raise, Clinical-stage, Autoimmune Diseases, FB102, SEC Filing, Underwriting Agreement, NASDAQ, FBRX, Equity Financing